The cell line is established cell culture, wherein the cells multiply in the apt growth medium and space for growth. Different cell lines are made from different cells. Cell lines enable stepwise alterations in the structure, physiology, and genetic makeup of cells under a customized environment. The cell line development market growth is mainly attributed to the increasing adoption of regenerative medicines, the rising prevalence of cancer across the globe, and soaring investments in R&D by pharmaceutical and biotechnology companies. Moreover, consistent research in drug discovery activities is further expected to foster market growth during the forecast period. However, the risk of cell line contamination is restricting the market growth.
To Get a Free Sample @ https://www.theinsightpartners.com/sample/TIPHE100001196/
The cell line development market was valued at US$ 4,160.42 million in 2019 and is projected to reach US$ 11,219.87 million by 2027; it is expected to grow at a CAGR of 13.3% from 2020 to 2027.
North America has been witnessing a growing number of COVID-19 cases since the viral outbreak. According to Worldometer, as of September 2, 2020, the number of cases has reached to 6,335,244, with 191,058 deaths, in the US. The pharmaceutical companies and research institutes have shifted their research activities in finding vaccines for COVID-19, thereby putting the development of other therapeutics on hold. Moreover, many research organizations are struggling with a wide range of challenges such as reduced funding, cancelled fundraising events, and shelving projects due to economic uncertainty. Thus, the abovementioned factors are hindering the growth of the cell line development market, and the impact is likely to persist for a certain time period.
Increasing Adoption of Regenerative Medicines Drives Cell Line Development Market Growth
Regenerative medicines have the potential to replace or heal tissues as well as organs damaged due to various factors, such as age, disease, or trauma; they also help normalize congenital defects. Over the last quarter of a century, there has been an emergence of a tissue engineering industry, which has now evolved into the broader area of regenerative medicines. Regenerative medicines are a rapidly growing interdisciplinary field with the involvement of engineering sciences to develop clinical therapies for maintenance, repair, replacement, and enhancement of biological functions. Cell line development is a crucial and invariable part of this field as it helps understand how to treat a wide range of medical conditions, from broken bones to neurodegenerative diseases. Further, regenerative medicines use cell-based models that have the potential to help researchers in early intervention treatment for degenerative diseases and traumatic injuries. Thus, the rise in the adoption of regenerative medicines is fostering the demand for cell line development in the coming years.
Based on type, the cell line development market is segmented into primary cell lines, hybridomas, continuous cell lines, and recombinant cell lines. The recombinant cell line segment held the largest share of the market in 2019. However, the hybridomas segment is anticipated to register the highest CAGR during the forecast period. The growth of the market for recombinant cell lines is attributed to rising demand for recombinant proteins, increasing use of recombinant cell lines for biotherapeutics, and growing demand for toxicity testing.
Based on product, the cell line development market is segmented into equipment, and media and reagent. The media and reagent segment held a larger share of the market in 2019. Moreover, it is anticipated to register a higher CAGR during the forecast period. The media contain crucial ingredients and compounds that regulate cell cycle. A culture medium consists of amino acids, inorganic salts, vitamins, glucose, and serum that act as precursors of hormones, growth factors, and attachment factors. Similarly, several reagents are used during the development of cell line.
Based on application, the cell line development market is segmented into drug discovery, bioproduction, and tissue engineering. The bioproduction segment held the largest share of the market in 2019. The growth of the segment is attributed to the wide availability of cell lines for bioproduction. Many of the market players are offering cell lines for bioproduction purposes. For instance, Creative Biogene provides comprehensive services for generating bioproduction stable cell lines. However, the drug discovery segment is anticipated to register the highest CAGR during the forecast period.
Product launches, mergers and acquisitions, collaborations, and expansions are the commonly adopted strategies by various companies to expand their footprint worldwide and meet the growing demand by expanding their respective product portfolios. The players operating in the cell line development market adopted the product innovations strategy to cater to the changing customer demands around the world, which also permits them to maintain their brand name in a global market. In April 2019, Lonza launched CellBio Services, a comprehensive portfolio of unique, custom-made solutions designed to meet specific, individual research application needs.
Cell Line Development Market – by Type
- Media & Reagent
Cell Line Development Market – by Application
- Drug Discovery
- Tissue Engineering
Cell Line Development Market– by Geography
- North America
- Asia Pacific(APAC)
- Middle East and Africa (MEA)
- South and Central America (SCAM)
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Selexis SA (JSR Corporation)
- BioFactura, Inc.
- Corning Incorporated
- Sartorius AG
- GENERAL ELECTRIC
- LakePharma, Inc.
- WuXiAppTec Group
To Purchase Report @ https://www.theinsightpartners.com/buy/TIPHE100001196/
The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive, and Defense.
Email: [email protected]